Method of reducing the harmful effects of orally or transdermally delivered nicotine
First Claim
Patent Images
1. A tobacco use cessation kit comprising:
- a first tobacco product that comprises nicotine and delivers a collective content of N′
-nitrosonornicotine (NNN), N′
-nitrosoanatabine (NAT), N′
-nitrosoanabasine (NAB), 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK) of less than 5.0 μ
g/g;
a second tobacco product that comprises an amount of nicotine that is less than the first tobacco product and delivers a collective content of N′
-nitrosonornicotine (NNN), N′
-nitrosoanatabine (NAT), N′
-nitrosoanabasine (NAB), 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK) of less than 5.0 μ
g/g, wherein said first tobacco product and said second tobacco product are cigarettes; and
a third tobacco product that comprises an amount of nicotine that is less than the amount of nicotine in said second tobacco product and delivers a collective content of N′
-nitrosonornicotine (NNN), N′
-nitrosoanatabine (NAT), N′
-nitrosoanabasine (NAB), 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK) of less than 5.0 μ
g/g, wherein said first tobacco product, said second tobacco product, and said third tobacco product are cigarettes and wherein said first tobacco product delivers less than 0.7 mg/g nicotine, said second tobacco product delivers less than 0.4 mg/g nicotine, and said third tobacco product delivers less than 0.5 mg/g nicotine.
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention generally relates to the reduction of the harmful effects of orally or transdermally delivered nicotine in conventional tobacco-use cessation programs. More specifically, embodiments concern methods of reducing the harmful effects of nicotine intake, associated with conventional tobacco-use cessation programs, by providing tobacco products, which contain a reduced amount of nicotine and/or tobacco specific nitrosamines (TSNAs).
123 Citations
1 Claim
-
1. A tobacco use cessation kit comprising:
-
a first tobacco product that comprises nicotine and delivers a collective content of N′
-nitrosonornicotine (NNN), N′
-nitrosoanatabine (NAT), N′
-nitrosoanabasine (NAB), 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK) of less than 5.0 μ
g/g;
a second tobacco product that comprises an amount of nicotine that is less than the first tobacco product and delivers a collective content of N′
-nitrosonornicotine (NNN), N′
-nitrosoanatabine (NAT), N′
-nitrosoanabasine (NAB), 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK) of less than 5.0 μ
g/g, wherein said first tobacco product and said second tobacco product are cigarettes; and
a third tobacco product that comprises an amount of nicotine that is less than the amount of nicotine in said second tobacco product and delivers a collective content of N′
-nitrosonornicotine (NNN), N′
-nitrosoanatabine (NAT), N′
-nitrosoanabasine (NAB), 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK) of less than 5.0 μ
g/g, wherein said first tobacco product, said second tobacco product, and said third tobacco product are cigarettes and wherein said first tobacco product delivers less than 0.7 mg/g nicotine, said second tobacco product delivers less than 0.4 mg/g nicotine, and said third tobacco product delivers less than 0.5 mg/g nicotine.
-
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeVector Tobacco Inc. (Vector Group Ltd.)
-
Original AssigneeVector Tobacco Inc. (Vector Group Ltd.)
-
InventorsJin, Wendy, Conkling, Mark, Albino, Anthony
-
Application NumberUS11/415,817Publication NumberTime in Patent OfficeDaysField of SearchUS Class Current131/270CPC Class CodesA24B 15/20 Biochemical treatmentA24B 15/243 NicotineA24B 15/245 NitrosaminesA61K 9/007 Pulmonary tract; AromatherapyC12N 15/8243 involving biosynthetic or m...
